Related Experiment Video
Updated: Apr 5, 2026
09:05
Measurement of Smooth Muscle Function in the Isolated Tissue Bath-applications to Pharmacology Research
Published on: January 19, 2015
150.4K
[Experience in using minipress in essential hypertension].
Terapevticheskii Arkhiv
|January 1, 1989
Summary
Minipress, an alpha 1-adrenoreceptor blocker, effectively treats stage II essential hypertension in over half of patients. This hypertension drug reduces vascular resistance and improves microcirculation with minimal impact on heart rate or stroke volume.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hypertension Research
Context:
- Essential hypertension is a common condition requiring effective treatment.
- Selective alpha 1-adrenoreceptor blockers represent a class of antihypertensive agents.
- Minipress is a specific drug within this pharmacological class.
Purpose:
- To investigate the hypotensive efficacy and side-effect profile of Minipress.
- To evaluate the long-term effects of Minipress on hemodynamics and microcirculation.
- To assess the impact of Minipress on total peripheral vascular resistance, stroke volume, and pulse rate.
Summary:
- Minipress demonstrated efficacy in 56.3% of patients with stage II essential hypertension.
- Side-effects were observed in 16.6% of patients.
- Long-term administration of Minipress (mean daily dose 3.4 ml) reduced total peripheral vascular resistance without significant changes in heart stroke volume or pulse rate, while improving microcirculatory blood flow.
Impact:
- Minipress offers a viable treatment option for essential hypertension with a manageable side-effect profile.
- The drug's mechanism involves reducing vascular resistance and enhancing microcirculation.
- Findings support Minipress's role in managing hypertension by improving hemodynamic parameters and blood flow dynamics.
Related Concept Videos
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
741
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
741
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
564
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564